Semi-Annual Report — FY2026 H1
What Modalis Therapeutics Corporation reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-14View the original on EDINET
How much it says
48Typical
What moved here
15named for the first time
Its own wording
29terms
Which filing this is
20/ 20newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period from 1 January to 30 June 2026, the company recognized R&D expenses, an operating loss and an interim net loss. On the funding side, cash and cash equivalents increased from the beginning of the period, primarily due to proceeds from the issuance of bonds, recorded as financing cash flows, and proceeds from the issuance of shares through the exercise of stock acquisition rights.
Komori's summary of this document, not the document's own words.48Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
61
Detailed
45
Typical
88
Very detailed
50
Typical
15
Almost nothing
68
Detailed
55
Typical
7
Almost nothing
11
Almost nothing
50
Typical
R&D spend9億円Money spent making new things.
Cash left over-7億円Cash from the business, less what went into equipment.
Spent on equipment2百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.